Menu
Search
|

Menu

Close
X

DexCom Inc DXCM.OQ (NASDAQ Stock Exchange Global Select Market)

56.08 USD
-0.32 (-0.57%)
As of 4:39 PM GMT
chart
Previous Close 56.40
Open 56.54
Volume 39,010
3m Avg Volume 453,975
Today’s High 56.88
Today’s Low 55.61
52 Week High 86.21
52 Week Low 42.63
Shares Outstanding (mil) 86.56
Market Capitalization (mil) 4,132.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.06 Mean rating from 17 analysts

KEY STATS

Revenue (mm, USD)
FY17
313
FY16
573
FY15
402
EPS (USD)
FY17
-0.456
FY16
-0.787
FY15
-0.722
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
6.53
5.77
Price to Book (MRQ)
vs sector
11.68
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
92.51
16.52
LT Debt to Equity (MRQ)
vs sector
92.51
12.22
Return on Investment (TTM)
vs sector
-13.69
14.43
Return on Equity (TTM)
vs sector
-21.66
16.13

EXECUTIVE LEADERSHIP

Terrance Gregg
Executive Chairman of the Board, Since 2015
Salary: $420,000.00
Bonus: $1,008,000.00
Kevin Sayer
President, Chief Executive Officer, Director, Since 2015
Salary: $475,000.00
Bonus: $581,133.00
Quentin Blackford
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Donald Abbey
Executive Vice President, Quality and Information Technology, Since 2017
Salary: $199,641.00
Bonus: $166,388.00
Andrew Balo
Executive Vice President - Clinical, Regulatory and Quality, Since 2015
Salary: $310,000.00
Bonus: $379,266.00

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

6340 Sequence Dr
SAN DIEGO   CA   92121-4356

Phone: +1858.2000200

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

SPONSORED STORIES